05.17.18

Leahy Comment On The FDA's Naming Of Drug Firms That Are Blocking Competition That Would Lead To Lower-Cost Generic Prescription Drugs

“More transparency, by FDA and others, is helpful to spotlight the abusive and anti-competitive tactics that we know some brand name drug companies use to block competition.  Understanding the problem is the first step, but acting on it is the vital next step.  With billions of dollars at stake, a database alone will not stop this behavior.  Nor can years of litigation through antitrust suits.  The good news is that Congress has a bipartisan and carefully crafted solution, ready to go, to end this conduct.  The best way to lower the price of prescription drugs is to meaningfully increase competition.  Our CREATES Act would do that, and it has equal support from Democrats and Republicans.”

Press Contact

David Carle: 202-224-3693